COVID-19 and Parkinson's Disease: frequency and clinical-sociodemographic profile in a patient sample
DOI:
https://doi.org/10.34024/rnc.2025.v33.19718Keywords:
Parkinson's disease, COVID-19, Prevalence, VaccineAbstract
Objectives. To investigate the frequency and symptoms of COVID-19, hospitalization data, and complications in individuals with Parkinson’s disease (PD) who were infected with SARS-CoV-2, comparing their clinical and sociodemographic profiles with those of non-infected individuals. Method. This is a retrospective observational study conducted at the Bias Fortes Outpatient Clinic of the Hospital das Clínicas (HC), the Medical Specialties Center (CEM) of Santa Casa de Belo Horizonte, and the Parkinson’s Association of Minas Gerais (ASPARMIG). Results. Between June and September 2022, attempts were made to contact 271 patients. However, 184 could not be reached due to outdated contact information or refusal to participate. Four patients had died (one due to COVID-19), and two were hospitalized for other reasons. In total, 63 patients (38 men and 25 women) participated in the study, with a mean age of 65.4±10.5 years and a mean PD duration of 10.3 ± 6.6 years. The majority of participants (93.6%) had received three or more doses of the COVID-19 vaccine, and 18 (28.6%) were diagnosed with the infection. The most reported symptoms were cough, myalgia, and headache. No patients required hospitalization or reported post-infection complications. No significant differences were observed between infected and non-infected patients regarding sociodemographic and clinical characteristics. Conclusions. Our findings indicate that the COVID-19 infection rate in individuals with PD is consistent with that reported in other studies. No post-infection complications were observed, and the general characteristics of infected and non-infected individuals with PD were similar.
Metrics
References
Xie NN, Zhang WC, Chen J, Tian FB, Song JX. Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review. Curr Med Sci 2023;43:1066-74. https://doi.org/10.1007/s11596-023-2797-3
Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrejón O, De la Cruz-Ku GA, Custodio N. Factors associated with COVID-19 in people with Parkinson’s disease: a systematic review and meta-analysis. Eur J Neurol 2021;28:3467-77. https://doi.org/10.1111/ene.14912
Yin J, Zhang S, Zheng Q, Feng Z. COVID-19 and Parkinson's disease: a single-center study and Mendelian randomization study. Sci Rep 2024;14:16517. https://doi.org/10.1038/s41598-024-66197-5
Artusi CA, Romagnolo A, Imbalzano G, Marchet A, Zibetti M, Rizzone MG, et al. COVID-19 in Parkinson's disease: Report on prevalence and outcome. Parkinsonism Relat Disord 2020;80:7-9. https://doi.org/10.1016/j.parkreldis.2020.09.008
Scherbaum R, Kwon EH, Richter D, Bartig D, Gold R, Krogias C, et al. Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany. Mov Disord 2021;36:1049-57. https://doi.org/10.1002/mds.28586
Salari M, Etemadifar M, Ashrafi F, Ommi D, Aminzade Z, Tehrani Fateh S. Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran. Parkinsonism Relat Disord 2021;89:90-2. https://doi.org/10.1016/j.parkreldis.2021.07.002
Khoshnood RJ, Zali A, Tafreshinejad A, Ghajarzadeh M, Ebrahimi N, Safari S, et al. Parkinson's disease and COVID-19: a systematic review and meta-analysis. Neurol Sci 2022;43:775-83. https://doi.org/10.1007/s10072-021-05756-4
Afraie M, Moradi G, Mohammadzedeh P, Azami M, Riyahifar S, Moradi Y. COVID-19 and Parkinson's disease: a systematic review and meta-analysis. Acta Neurol Belg 2023;123:1209-23. https://doi.org/10.1007/s13760-022-02141-6
El-Qushayri AE, Ghozy S, Reda A, Kamel AMA, Abbas AS, Dmytriw AA. The impact of Parkinson's disease on manifestations and outcomes of Covid-19 patients: A systematic review and meta-analysis. Rev Med Virol 2022;32:e2278. https://doi.org/10.1002/rmv.2278
Baschi R, Luca A, Nicoletti A, Caccamo M, Cicero CE, D'Agate C, et al. Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown. Front Psychiatr 2020;11:590134. https://doi.org/10.3389/fpsyt.2020.590134
Brown EG, Chahine LM, Goldman SM, Korell M, Mann E, Kinel DR, et al. The Effect of the COVID-19 Pandemic on People with Parkinson's Disease. J Parkinsons Dis 2020;10:1365-77. https://doi.org/10.3233/JPD-202249
Cilia R, Bonvegna S, Straccia G, Andreasi NG, Elia AE, Romito LM, et al. Effects of COVID-19 on Parkinson's Disease Clinical Features: A Community-Based Case-Control Study. Mov Disord 2020;35:1287-92. https://doi.org/10.1002/mds.28170
Simieli L, Santinelli FB, Costa EC, Kuroda MH, Oliveira LR, Penedo T, et al. Perception of COVID-19 Pandemic by Brazilian People With Parkinson's Disease and Multiple Sclerosis. Front Psychol 2022;13:718313. https://doi.org/10.3389/fpsyg.2022.718313
Leta V, Boura I, van Wamelen DJ, Rodriguez-Violante M, Antonini A, Chaudhuri KR. Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism. Int Rev Neurobiol 2022;165:63-89. https://doi.org/10.1016/bs.irn.2022.04.004
Albuquerque C. Pandemia diminui número e muda perfil de internações no SUS em 2020. Observatório de Política e Gestão Hospitalar (acessado em 01/10/2024). Disponível em: https://www.observatoriohospitalar.fiocruz.br/debates-e-opinioes/pandemia-diminui-numero-e-muda-perfil-de-internacoes-no-sus-em-2020
Vasconcellos PRO, Rizzotto MLF, Taglietti M. Morbidade hospitalar e mortalidade por Doença de Parkinson no Brasil de 2008 a 2020. Saúde Debate 2023;47:196-206. https://doi.org/10.1590/0103-1104202313714
Del Prete E, Francesconi A, Palermo G, Mazzucchi S, Frosini D, Morganti R, et al. Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region. J Neurol 2021;268:1179-87. https://doi.org/10.1007/s00415-020-10002-6
Zhai H, Lv Y, Xu Y, Wu Y, Zeng W, Wang T, et al. Characteristic of Parkinson's disease with severe COVID-19: a study of 10 cases from Wuhan. J Neural Transm 2021;128:37-48. https://doi.org/10.1007/s00702-020-02283-y
Shahgholi L, De Jesus S, Wu SS, Pei Q, Hassan A, Armstrong MJ, et al. Hospitalization and rehospitalization in Parkinson disease patients: Data from the National Parkinson Foundation Centers of Excellence. PLoS One 2017;12:e0180425. https://doi.org/10.1371/journal.pone.0180425
Santos-García D, Oreiro M, Pérez P, Fanjul G, Paz González JM, Feal Painceiras MJ, et al. Impact of coronavirus disease 2019 pandemic on Parkinson’s disease: a cross-sectional survey of 568 Spanish patients. Mov Disord 2020;35:1712-6. https://doi.org/10.1002/mds.28261
Balci B, Aktar B, Buran S, Tas M, Donmez Colakoglu B. Impact of the COVID-19 pandemic on physical activity, anxiety, and depression in patients with Parkinson's disease. Int J Rehabil Res 2021;44:173-6. https://doi.org/10.1097/MRR.0000000000000460
Silva LCS, Padro MA, Fernandes MR, Filho AVM, Sousa MC, Costa TAM, et al. Inconformidades nos registros em prontuários: opinião dos trabalhadores de saúde. Res Soc Develop 2021;10:e294101220587. https://doi.org/10.33448/rsd-v10i12.20587
Dainesi SM. Como melhorar o recrutamento de pacientes em estudos clínicos? Rev Assoc Med Bras 2004;50:241. https://doi.org/10.1590/S0104-42302004000300017
Siddiqi B, Koemeter-Cox A. A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson's Research and Care. J Parkinsons Dis 2021;11:905-8. https://doi.org/10.3233/JPD-212593
Brown EG, Chahine LM, Goldman SM, Korell M, Mann E, Kinel DR, et al. The effect of the COVID-19 pandemic on people with Parkinson’s disease. J Parkinsons Dis 2020;10:1365-77. https://doi.org/10.3233/JPD-202249
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Aline Michele Batista de Figueiredo Feital, Bernardo Machado Gonçalves, Thales de Moraes Ogawa, Paula Luciana Scalzo
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
Accepted 2025-01-21
Published 2025-02-12
